Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Open-label, Multicenter, Dose-ranging Study to Investigate Safety and Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types

NCT06034860 is registered in ClinicalTrials.gov with Molecular Templates, Inc. as lead sponsor.

NCT NCT06034860
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06034860 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Open-label, Multicenter, Dose-ranging Study to Investigate Safety and Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types
Lead sponsor
Molecular Templates, Inc.
Phase
Phase 1
Overall status
Terminated
Start date
November 1, 2023
Completion date
October 31, 2024
Enrollment
15 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

cervical cancer, esophageal squamous cell carcinoma, hepatocellular carcinoma, melanoma, mesothelioma, microsatellite instability high, mismatch repair deficiency, non small cell lung cancer, renal cell carcinoma, squamous cell carcinoma of head and neck, urothelial carcinoma